8-K

0001193125-24-046240.txt : 20240226 0001193125-24-046240.hdr.sgml : 20240226 20240226163239 ACCESSION NUMBER: 0001193125-24-046240 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240222 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240226 DATE AS OF CHANGE: 20240226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HCA Healthcare, Inc. CENTRAL INDEX KEY: 0000860730 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 273865930 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11239 FILM NUMBER: 24679453 BUSINESS ADDRESS: STREET 1: ONE PARK PLZ CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6153449551 MAIL ADDRESS: STREET 1: ONE PARK PLAZA CITY: NASHVILLE STATE: TN ZIP: 37203 FORMER COMPANY: FORMER CONFORMED NAME: HCA Holdings, Inc. DATE OF NAME CHANGE: 20101126 FORMER COMPANY: FORMER CONFORMED NAME: HCA INC/TN DATE OF NAME CHANGE: 20010627 FORMER COMPANY: FORMER CONFORMED NAME: HCA THE HEALTHCARE CO DATE OF NAME CHANGE: 20010419 8-K 1 d789841d8k.htm 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 26, 2024 (February 22, 2024)

HCA Healthcare, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware

001-11239

27-3865930

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

One Park Plaza, Nashville,

Tennessee

37203

(Address of Principal Executive Offices)

(Zip Code)

(615) 344-9551

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class

Trading
Symbol(s)

Name of each exchange

on which registered

Common Stock, $.01 par value per share

HCA

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

2024 Executive Officer Performance Excellence Program

On February 22, 2024, the Compensation Committee (the “Committee”) of the Board of Directors of HCA Healthcare, Inc. (the “Company”) adopted the 2024 Executive Officer Performance Excellence Program (the “Executive Officer PEP”). Under the Executive Officer PEP, the executive officers of the Company shall be eligible to earn performance awards based upon the achievement of certain specified performance targets. The Executive Officer PEP award opportunities for the Company’s named executive officers and other executive officers are weighted (i) 80% for the achievement of certain EBITDA (as defined in the Executive Officer PEP) targets and (ii) 20% for the achievement of targets associated with certain quality metrics. The EBITDA weighted portion of the American Group, Atlantic Group and National Group Presidents’ Executive Officer PEP awards is based 50% on Company EBITDA and 50% on EBITDA for their respective Group. The quality weighted portion of the Executive Officer PEP is based on each of the following quality categories: Healthcare-Associated Infections and Sepsis (30%), Complication and Mortality (30%) and Care Experience (40%) (each as defined in the Executive Officer PEP).

Target Executive Officer PEP award opportunities for 2024 for the Company’s named executive officers¹ are as follows:

•

170% of base salary for Samuel N. Hazen, our Chief Executive Officer;

•

125% of base salary for Jon M. Foster, our Executive Vice President and Chief Operating Officer; and

•

85% of base salary for Michael R. McAlevey, our Senior Vice President and Chief Legal Officer (to be increased to 100%, effective April 1, 2024, in connection with Mr. McAlevey’s appointment as Executive Vice President – Chief Legal and Administrative Officer).

¹	William B. Rutherford intends to retire as Executive Vice President and Chief Financial Officer, effective May 1, 2024, and will therefore not participate in the Executive Officer PEP.

With respect to the EBITDA weighted portion of the Executive Officer PEP, participants will receive 100% of the EBITDA weighted portion of the target award for target performance, 25% of the EBITDA weighted portion of the target award for a minimum acceptable (threshold) level of performance, and a maximum of 200% of the EBITDA weighted portion of the target award for maximum performance. With respect to the quality weighted portion of the Executive Officer PEP, participants will receive 100% of the quality weighted portion of the target award applicable to each individual quality of care metric for performance at the target level of performance for such metric, 0% of the quality weighted portion of the target award applicable to each individual quality of care metric for performance at or below the minimum (threshold) level of performance for such metric and a maximum of 200% of the quality weighted portion of the target award applicable to each individual quality of care metric for maximum performance for such metric; provided, that, in the event the Company’s actual EBITDA is less than 90% of the target level of EBITDA, there will be no payment with respect to the quality weighted portion of the Executive Officer PEP.

Awards pursuant to the Executive Officer PEP will be paid solely in cash. No payments will be made for performance below specified threshold amounts. Payouts between threshold and target or target and maximum will be calculated by the Committee in its sole discretion using straight-line interpolation. The Committee may make adjustments to the terms and conditions of awards, the performance criteria, and/or associated targets under the Executive Officer PEP in recognition of unusual or nonrecurring events affecting a participant or the Company, or the financial statements of the Company, or in certain other instances specified in the Executive Officer PEP. In addition, in the event the applicable governmental agency adjusts any of the definitions of the quality of care metrics during the performance period, appropriate adjustments shall be made to the targets, or results, or both, to properly account for such changes, in the Committee’s sole discretion. Awards pursuant to the Executive Officer PEP are also subject to discretionary recovery or adjustment by the Company in certain circumstances in which the operating results on which the payment was based were restated or otherwise adjusted or in the event a participant’s conduct is not in good faith and materially disrupts, damages, impairs or interferes with the business of the Company and its affiliates. Any award granted pursuant to the Executive Officer PEP shall also be subject to mandatory repayment by the participant to the Company as set forth in the Executive Officer PEP.

The foregoing description of the Executive Officer PEP does not purport to be complete and is qualified in its entirety by reference to the Executive Officer PEP, a copy of which is attached to this report as Exhibit 10.1 and incorporated herein by reference.

Compensation of Michael R. McAlevey as Executive Vice President – Chief Legal and Administrative Officer

On February 16, 2024, the Board of Directors appointed Michael R. McAlevey as the Executive Vice President – Chief Legal and Administrative Officer of the Company, effective April 1, 2024. On February 22, 2024, the Committee approved a base salary of $990,000 for Mr. McAlevey beginning on the effective date of his appointment. In addition, in connection with his appointment, the Committee determined to grant Mr. McAlevey a long-term equity incentive award with a total target grant date value of $500,000 (the “Equity Award”), with fifty percent (50%) of the target award in the form of stock appreciation rights which vest over four years and the other fifty percent (50%) of the target award in the form of performance share units which vest upon achievement of a cumulative three year earnings per share goal, in each case, in accordance with the terms and conditions of the award agreements and the 2020 Stock Incentive Plan for Key Employees of HCA Healthcare, Inc. and its Affiliates. The Equity Award is anticipated to be granted in late April 2024.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits:


Exhibit 10.1		HCA Healthcare, Inc. 2024 Executive Officer Performance Excellence Program

Exhibit 104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


		HCA HEALTHCARE, INC.

		/s/ John M. Franck II
		John M. Franck II
		Vice President – Legal & Corporate Secretary

Date: February 26, 2024

EX-10.1 2 d789841dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

HCA HEALTHCARE, INC.

2024 EXECUTIVE OFFICER PERFORMANCE EXCELLENCE PROGRAM

Purpose and Administration of the Program

The 2024 Executive Officer Performance Excellence Program (the “Program”) has been established by HCA Healthcare, Inc. (the “Company”) to encourage outstanding performance from its executive officers. Awards under the Program shall be administered as “Performance-Based Awards” pursuant to the 2020 Stock Incentive Plan for Key Employees of HCA Healthcare, Inc. and its Affiliates (the “2020 Plan”) and shall be subject to the HCA Healthcare, Inc. Compensation Recoupment Policy (the “Recoupment Policy”). Subject to applicable law, all designations, determinations, interpretations, and other decisions under or with respect to the Program or any award shall be within the sole discretion of the Compensation Committee of the Board of Directors of HCA Healthcare, Inc., including any subcommittee formed pursuant to Section 3(a) of the 2020 Plan (the “Committee”), may be made at any time and shall be final, conclusive and binding upon all persons. Designations, determinations, interpretations, and other decisions made by the Committee with respect to the Program or any Award, including but not limited to the application of the Discretionary Recoupment Terms, described herein, need not be uniform and may be made selectively among Participants, whether or not such Participants are similarly situated.

Participation

All officers of the Company who have been designated by the Company as “executive officers” of the Company during 2024 (the “Fiscal Year”) are eligible to receive an award pursuant to the Program (each, a “Participant”).

Incentive Calculation and Payment of Awards

Awards shall be calculated based on the financial results for the Fiscal Year and most recently available quality and care experience results and shall be paid within two and one-half months following the end of the Fiscal Year. No awards will be paid to a Participant until the Chief Executive Officer has affirmed that the Participant’s behavior and actions during the Fiscal Year were consistent with the Company’s stated mission and values, the Code of Conduct and other regulatory requirements.

The Committee will make awards pursuant to the Program (each, an “Award”) as set forth on Schedule A hereto, on such terms as the Committee may prescribe based on the performance criteria set forth on Schedule A hereto and such other factors as it may deem appropriate. The targets for the performance criteria shall be determined by the Committee, in its discretion. The Committee shall determine and certify whether and to what extent each performance or other goal has been met prior to the payment of any Award hereunder. A Participant is required to remain employed with the Company through the end of the Fiscal Year in order to have a legally binding right to the Award.

Awards pursuant to the Program will be paid solely in cash.

Except as provided for in any employment agreement or as the Committee may otherwise determine in its sole and absolute discretion, termination of a Participant’s employment prior to the end of the Fiscal Year will result in the forfeiture of the Award by the Participant, and no payments shall be made with respect thereto.

This Program is not a “qualified” plan for federal income tax purposes, and any payments are subject to applicable tax withholding requirements.

Adjustments for Unusual or Nonrecurring Events

In addition to any adjustments enumerated in the definition of the performance goals set forth on Schedule A hereto, the Committee is hereby authorized to make adjustments in the terms and conditions of awards, the performance criteria, and/or associated targets under the following circumstances: (1) in recognition of unusual or nonrecurring events affecting any Participant, the Company, or any subsidiary or affiliate, or the financial statements of the Company or of any subsidiary or affiliate; (2) in the event of changes in applicable laws, regulations or accounting principles; or (3) in the event the Committee determines that such adjustments are appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Program.

The Committee is also authorized to adjust performance targets or reduce awards to avoid unwarranted windfalls.

Recoupment

Any award granted pursuant to this Program is subject to mandatory repayment by the Participant to the Company to the extent that such Participant is, or in the future becomes, required to repay any such amount pursuant to (a) the Recoupment Policy, as such policy may be amended from time to time, or (b) any other applicable laws, regulations or standards that impose mandatory recoupment under circumstances set forth in such applicable requirements, including the Sarbanes-Oxley Act of 2002.

Separate from, and in addition to the Recoupment Policy and any other applicable mandatory recoupment requirements referenced in the preceding paragraph, any incentive compensation earned or paid to a Participant pursuant to this Program shall also be subject to discretionary recoupment by the Company in the event of certain circumstances and subject to certain conditions set forth in the remainder of this section (the “Discretionary Recoupment Terms”).

The Company may recover any incentive compensation awarded or paid pursuant to this Program based on:

(i)

achievement of financial results that were subsequently the subject of a restatement due to material noncompliance with any financial reporting requirement under either GAAP or the federal securities laws, other than as a result of changes to accounting rules and regulations, regardless of individual fault;

(ii)

a subsequent finding that the financial information or performance metrics used by the Committee to determine the amount of the incentive compensation were materially inaccurate, regardless of individual fault; or

(iii)

a Participant’s conduct which is not in good faith and which materially disrupts, damages, impairs or interferes with the business of the Company and its affiliates.

Subsequent changes in status, including retirement or termination of employment, do not affect the Company’s rights to recover compensation under these Discretionary Recoupment Terms.

The Committee will administer the Discretionary Recoupment Terms and exercise its discretion and business judgment in the fair application of the Discretionary Recoupment Terms based on the facts and circumstances as it deems relevant in its sole discretion. More specifically, the Committee shall determine in its discretion any appropriate amounts to recoup, the officers from whom such amounts shall be recouped (which need not be all officers who received the incentive compensation at issue) and the timing and form of recoupment; provided, that only compensation paid or settled within three years prior to the Committee taking action under these Discretionary Recoupment Terms shall be subject to recoupment; provided further, that any recoupment pursuant to clause (i) or (ii) of the Discretionary Recoupment Terms shall not exceed the portion of any applicable incentive compensation paid hereunder that is in excess of the amount of such compensation that would have been paid or granted based on the actual, restated financial statements or actual level of the applicable financial or performance metrics as determined by the Committee in its sole discretion.

For avoidance of doubt, the Company may set off the amounts of any such required recoupment against any amounts otherwise owed by the Company to a Participant as determined by the Committee in its sole discretion, but only to the extent such offset complies with the requirements of Section 409A of the Code and the guidance issued thereunder.

If any restatement of the Company’s financial results indicates that the Company should have made higher performance-based payments than those actually made under the Program for a period affected by the restatement, then the Committee shall have discretion, but not the obligation, to cause the Company to make appropriate incremental payments to affected Participants then-currently employed by the Company. The Committee will determine, in its sole discretion, the amount, form and timing of any such incremental payments, which shall be no more than the difference between the amount of performance-based compensation that was paid or awarded and the amount that would have been paid or granted based on the actual, restated financial statements.

No Right to Employment

The grant of an award shall not be construed as giving a Participant the right to be retained in the employ of the Company or any subsidiary or affiliate.

No Trust or Fund Created

Neither the Program nor any award shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company or any subsidiary or affiliate and a Participant or any other person. To the extent that any person acquires a right to receive payments from the Company or any subsidiary or affiliate pursuant to an award, such right shall be no greater than the right of any unsecured general creditor of the Company or any subsidiary or affiliate.

No Rights to Awards

No person shall have any claim to be granted any award and there is no obligation for uniformity of treatment among Participants. The terms and conditions of awards, if any, need not be the same with respect to each Participant. The Company reserves the right to terminate the Program at any time in the Company’s sole discretion.

Section 409A of the Internal Revenue Code

This Program is intended to comply with Section 409A of the Code and will be interpreted in a manner intended to comply with Section 409A of the Code.

Interpretation and Governing Law

This Program shall be governed by and interpreted and construed in accordance with the internal laws of the State of Delaware, without reference to principles of conflicts or choices of laws. In the event the terms of this Program are inconsistent with the terms of any written employment agreement between a Participant and the Company, the terms of such written employment agreement shall govern the Participant’s participation in the Program. Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in the 2020 Plan.

Schedule A

2024 PEP Measures and Weightings


	Target PEP Opportunity¹ (% of base salary)			EBITDA Weight²			Quality Weight³
CEO		170	%		80	%		20	%
EVP and Chief Operating Officer		125	%		80	%		20	%
EVP and Chief Financial Officer		110	%		80	%		20	%
EVP (Chief Clinical Officer, Chief Legal & Administrative Officer)		100	%		80	%		20	%
Group Presidents		85	%		80	%		20	%
Other Participants		65-85	%		80	%		20	%

¹	PEP Opportunity: Target PEP Opportunities are expressed as a percentage of base salary as approved by the Committee. Maximum PEP opportunity payouts shall not exceed 200% of the Target PEP Opportunity stated above for any Participant.

EBITDA Weight: For the minimum acceptable (threshold) level of performance with respect to the EBITDA measure, a Participant may receive 25% of the EBITDA-weighted portion of the Target PEP Opportunity. For target level of performance with respect to the EBITDA measure, a Participant may receive 100% of the EBITDA-weighted portion of the Target PEP Opportunity. For the maximum level of performance with respect to the EBITDA measure, a Participant may receive 200% of the EBITDA-weighted portion of the Target PEP Opportunity. Payouts for performance between the threshold and maximum levels of performance for Participants will be calculated by the Committee in its sole discretion using straight-line interpolation.

The EBITDA weighted portion of the American Group, Atlantic Group, and National Group Presidents’ PEP awards will be based 50% on Company EBITDA performance and 50% on their respective Group’s EBITDA performance.

For the purposes of this calculation, EBITDA means earnings before interest, income taxes, depreciation, amortization, net income attributable to non-controlling interests, gains or losses on sales of facilities, gains or losses on extinguishment of debt, legal claim costs (benefits), asset or investment impairment charges, restructuring charges, expenses for share-based compensation under ASC Topic 718, and any other gains or charges resulting from significant, unusual and/or nonrecurring events, as described in management’s discussion and analysis of financial condition and results of operations appearing in the Company’s annual report for the Fiscal Year, as determined in good faith by the Board or the Committee in consultation with the CEO. In the event the Company disposes of any facility during the Fiscal Year, the EBITDA target for such year shall be adjusted appropriately (based on the number of days during the year for which the facility was owned) to reflect the disposition. In the event the Company acquires a facility during the Fiscal Year where the acquired facility is excluded from the Fiscal Year budget, the EBITDA attributable to such facility will not be included in the calculation of the EBITDA performance for the Fiscal Year.

³	Quality Weight: The Quality Weight for each Participant is based on each of the following three quality categories: Healthcare-Associated Infections and Sepsis (30%), Complication and Mortality (30%) and Care Experience (40%) (as defined below).

For performance at or below the minimum acceptable (threshold) level of performance with respect to each individual quality metric, a Participant will not receive a payout for that metric. For target level of performance with respect to each individual quality metric, a Participant may receive 100% of the quality-weighted portion of the PEP opportunity tied to that individual quality metric. For maximum level of performance with respect to each quality metric, a Participant may receive 200% of the quality-weighted portion of the PEP opportunity tied to that individual metric. Payouts for quality performance between the threshold and maximum levels of performance for each quality metric for Participants will be calculated by the Committee in its sole discretion using straight-line interpolation from 0 – 200%.

In the event the Company’s actual EBITDA is less than 90% of the target level of EBITDA set by the Committee, there will be no payout with respect to the quality-weighted portion of PEP opportunity.

Healthcare Associated Infections metrics are Central Line-Associated Blood Stream Infection (CLABSI), Catheter-Associated Urinary Tract Infection (CAUTI), Surgical Site Infections (SSI), Methicillin Resistant Staphylococcus Aureus (MRSA) and Clostridium difficile (C. diff) for the Centers for Medicare and Medicaid Services (CMS) reportable patient populations as defined by the Centers for Disease Control and Prevention’s National Healthcare Safety Network (CDC – NHSN). The following inpatient core measure is also included: Sepsis Bundle (SEP-1) as developed by The Joint Commission and the Centers for Medicare and Medicaid Services (CMS) and set forth in the Specifications Manual for National Hospital Inpatient Quality Measures.

The Risk-Adjusted CHOIS Mortality and Complication Index Values are calculated for an all payer population using the Merative model or such successor models as appropriate, as determined by the Committee. The indices are calculated internally and published to the Company’s CHOIS application.

The Care Experience metric for inpatients is the CMS Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) overall rating top box score (CMS defines the “top box” score for the overall rating question to be a response of nine or ten on the CMS HCAHPS survey). The Care Experience metric for emergency room patients is the Press Ganey Emergency Room overall rating “top box” score (Press Ganey defines the top box score for the overall question to be a response of Very Good on the Patient Experience Emergency Room survey).

In the event the applicable governmental agency adjusts any of the definitions of the quality metrics set forth above during the performance period, appropriate adjustments shall be made to the targets, or results, or both, to properly account for such changes, in the Committee’s sole discretion.

In the event the Company divests, acquires or opens new facilities during the measurement period, the divested, acquired or newly opened facilities will be excluded for purposes of calculating the Company’s performance on the quality and care experience-weighted metrics.

The threshold, target and maximum EBITDA performance levels and other goals shall be set by the Committee in its sole discretion.

EX-101.SCH 3 hca-20240222.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 hca-20240222_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 hca-20240222_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Feb. 22, 2024
Cover [Abstract]
Amendment Flag	false
Entity Central Index Key	0000860730
Document Type	8-K
Document Period End Date	Feb. 22, 2024
Entity Registrant Name	HCA Healthcare, Inc.
Entity Incorporation State Country Code	DE
Entity File Number	001-11239
Entity Tax Identification Number	27-3865930
Entity Address, Address Line One	One Park Plaza
Entity Address, City or Town	Nashville
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37203
City Area Code	(615)
Local Phone Number	344-9551
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common Stock, $.01 par value per share
Trading Symbol	HCA
Security Exchange Name	NYSE
Entity Emerging Growth Company	false

EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d789841d8k.htm hca-20240222.xsd hca-20240222_lab.xml hca-20240222_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d789841d8k.htm": { "nsprefix": "hca", "nsuri": "http://hcahealthcare.com/20240222", "dts": { "inline": { "local": [ "d789841d8k.htm" ] }, "schema": { "local": [ "hca-20240222.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "hca-20240222_lab.xml" ] }, "presentationLink": { "local": [ "hca-20240222_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-02-22_to_2024-02-22", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d789841d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-02-22_to_2024-02-22", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d789841d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://hcahealthcare.com//20240222/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001193125-24-046240-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-046240-xbrl.zip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�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d789841d8k_htm.xml IDEA: XBRL DOCUMENT 0000860730 2024-02-22 2024-02-22 false 0000860730 8-K 2024-02-22 HCA Healthcare, Inc. DE 001-11239 27-3865930 One Park Plaza Nashville TN 37203 (615) 344-9551 false false false false Common Stock, $.01 par value per share HCA NYSE false